Shots:

• Janssen to pay ~$25M milestone payments to Arrowhead with the onset of trial and has begun the dosing of patients in REEF-1(NCT03982186) P-IIB study involving assessing of JNJ-3989- JNJ-6379- NA- and/or PBO in 450 patients with chronic hepatitis B virus infection for 48 wks.- evaluating its safety and efficacy
• Additionally- in Oct 2018 Arrowhead collaborated with Janssen to develop and commercialize Arrowhead’s ARO-HBV
• JNJ-3989 (SC) is an investigational antiviral liver-targeting candidate designed to treat chronic HBV infection via the ribonucleic acid interference (RNAi) mechanism. JNJ-6379 (PO) is capsid assembly modulator of the class that forms normal capsid structures (CAM-N)

Click here to read full press release/ article |

Ref: Arrowhead Pharmaceuticals | Image: Janssen